![]() | ![]() |
Formats:
|
||||||||||||||||||||||||||||||||||||
Copyright © 2008 by The National Academy of Sciences of the USA Biophysics MicroRNA regulation of a cancer network: Consequences of the feedback loops involving miR-17-92, E2F, and Myc aMathematical Biosciences Institute, Ohio State University,1735 Neil Avenue, Columbus, OH 43210; and bDivision of Pulmonary, Allergy, Critical Care, Sleep Medicine, College of Medicine, Ohio State University, Columbus, OH 43210 1To whom correspondence should be addressed. E-mail: afriedman/at/mbi.osu.edu Contributed by Avner Friedman, November 4, 2008 .Author contributions: B.D.A. designed research; B.D.A. and Y.K. performed research; B.D.A., M.G.P.-H., A.F., and C.B.M. analyzed data; and B.D.A. and C.B.M. wrote the paper. Received September 3, 2008. Freely available online through the PNAS open access option. This article has been cited by other articles in PMC.Abstract The transcription factors E2F and Myc participate in the control of cell proliferation and apoptosis, and can act as oncogenes or tumor suppressors depending on their levels of expression. Positive feedback loops in the regulation of these factors are predicted—and recently shown experimentally—to lead to bistability, which is a phenomenon characterized by the existence of low and high protein levels (“off” and “on” levels, respectively), with sharp transitions between levels being inducible by, for example, changes in growth factor concentrations. E2F and Myc are inhibited at the posttranscriptional step by members of a cluster of microRNAs (miRs) called miR-17-92. In return, E2F and Myc induce the transcription of miR-17-92, thus forming a negative feedback loop in the interaction network. The consequences of the coupling between the E2F/Myc positive feedback loops and the E2F/Myc/miR-17-92 negative feedback loop are analyzed using a mathematical model. The model predicts that miR-17-92 plays a critical role in regulating the position of the off–on switch in E2F/Myc protein levels, and in determining the on levels of these proteins. The model also predicts large-amplitude protein oscillations that coexist with the off steady state levels. Using the concept and model prediction of a “cancer zone,” the oncogenic and tumor suppressor properties of miR-17-92 is demonstrated to parallel the same properties of E2F and Myc. MicroRNAs (miRs) are small noncoding RNAs, 18–24 nt in length, that are predicted to regulate the expression of approximately one-third of all human genes (1, 2). This regulation occurs posttranscriptionally through miR binding to mRNA targets leading to target degradation or inhibition of translation. Current target-prediction computer programs (3, 4) often predict that a miR could target tens to hundreds of genes, and that a gene can be targeted by many miRs—thus, the expectation that miRs play important roles in coordinating many cellular processes, particularly those involved in development and disease (5). Indeed, miRs have been implicated in various cancers, acting either as oncogenes or tumor suppressor genes (6). In this article, we investigate the role of a set of miRs in the important “cancer network” shown in Fig. 1
The extent to which miRs change the levels of their target mRNAs is marginal compared with the effect of other regulators such as transcription factors and posttranslational protein modifiers (10). Thus, it is thought that the primary role of miRs is to modulate or fine-tune the dynamics of regulatory networks (10–13). The significance of this role is now increasingly recognized as there are now many reported cases in which abnormal miR expressions correlate with cancer development (reviewed in ref. 6). Here, we focus on miR-17-92, which behaves as an oncogene or a tumor suppressor in different situations (2, 14). The miR-17-92 cluster is a polycistronic gene located in human chromosome 13 ORF 25 (C13orf25) located at 13q31-q32. The cluster is composed of 7 mature miRs, namely, miR-17–5p, miR-17–3p, miR-18a, miR-19a, miR-20a, miR-19b, and miR-92–1 (Fig. 2
Among the experimentally validated targets of some miR-17-92 cluster members are the transcription factors Myc, E2F1, E2F2, and E2F3; interestingly, these same factors have been shown to induce the transcription of miR-17-92 (reviewed in ref. 14). The negative feedback loops thus formed are depicted in Fig. 2
Formulation of the Model Dimensionless Equations. Fig. 2
The constant term α in Eq. 1 stands for constitutive protein expression due to signal transduction pathways stimulated by growth factors present in the extracellular medium. The parameter α therefore corresponds to an experimentally controllable condition such as the concentration of nutrients in the cell culture medium. The right-most term in Eq. 1 is a first-order protein degradation term with fixed rate coefficient of δ. The constant term β in Eq. 2 represents p-independent constitutive transcription of m. The second term in Eq. 2 is the rate of p-induced transcription of m (assumed to be first order in p for simplicity), and the last term is a degradation term with rate coefficient γ. Delay Differential Equation. Step 1 in Fig. 2
Solving for the Steady States. The steady states of the system of Eqs. 3 and 4 are determined by equating the right-hand sides to zero. After eliminating μ in the steady equations, we obtain the following cubic polynomial whose non-negative roots give the steady states of (symbolized by s):
Parameter Values and Numerical Solution of the Differential Equations. The parameter ε is expected to be less than unity because miRs are typically more stable than proteins; for example, δ for E2F1 and Myc are ≈0.25 h−1 and ≈0.7 h−1, respectively (21), and γ ≈ 0.02 h−1 (22). The value of ε = 0.02 is used in our computer simulations (noting that δ for Myc is of order unity, and making allowances for the other E2Fs besides E2F1). An estimate of k1 for E2F1 is ≈0.4 μM h−1 and Γ1 ≈0.1 μM2 (21). We arbitrarily set (k2/β) ≈3 μM−1 so that Γ′1 ≈1 and κ ≈5 (the parameter β is assumed to be manipulated experimentally via gene transfection, for example). The dimensionless parameters α′ and Γ′2—whose values can be tuned experimentally—are allowed to vary in the ranges 0–0.4 and 0–2.5, respectively, to explore the effect of increasing rate of growth factor-induced protein synthesis and inhibition efficiency of the miRs. The differential equations of the model are solved using the computer software described in Methods. Results and Discussion Steady States of the Model and Significance of the Parameter α′. According to Eq. 8, the steady states of m and p increase or decrease in the same direction. This model prediction agrees with observations in various tumors that levels of Myc and miR-17-92 are both increased (23, 24). The model also clarifies the interpretation of Hayashita et al. (23) that members of the miR-17-92 cluster promote proliferation—this is because increase in the miR level correlates with increase in the levels of Myc or E2F, which are both proliferative. The steady state s as a function of the parameter α′ for different values of Γ′2 is shown in Fig. 4
With parameters satisfying the relationships given in Eq. 10, the model predicts that there is a range of α′ in which the system has 3 coexisting steady states (e.g., those with Γ′2 = 0, 1, 1.5, 1.8, 2). For example, for the curve with Γ′2 = 1.8, values of α′ from 0.05 (corresponding to the left knee of the curve) to 0.18 (right knee) give 3 steady states. We interpret the “right knee” of a steady-state diagram as a “switch-on” point at which a sharp irrevocable increase in protein level occurs until the upper steady state (the “on” position) is attained. In other words, the model predicts that there exists a threshold in growth-factor requirement for cells to “turn on” the protein synthesis. (We interpret the low protein steady states in Fig. 4 Significance of the Parameter Γ′2 and miR Regulation of Protein Levels. The dimensionless parameter Γ′2 represents the inhibition efficiency of miR-17-92 against its target proteins. The expression of Γ′2 in terms of the 4 parameters Γ2, k2, β, and γ (Eq. 5) suggests the ways to manipulate the miR inhibition efficiency experimentally. For example, Γ′2 can be increased by increasing Γ2 or k2, or by decreasing β or γ. The dependence of Γ′2 on β seems counterintuitive because Eq. 5 states that an increase in the constitutive or p-independent expression of miR-17-92 leads to a decrease in the miR inhibition efficiency. The case of Γ′2 = 0 represents any of the following situations: deletion of the miR-17-92 cluster; members of the cluster do not bind the transcripts of the target proteins (p) perhaps due to mutations; p does not induce expression of miR-17-92 (case of k2 = 0). Although p is no longer coupled to m, the 1-dimensional model of the autocatalytic variable p is still capable of exhibiting 3 steady states for α′ between 0 and ≈0.05 (see Fig. 4 Two key observations can be made from Fig. 4 The model also predicts 3 qualitatively different types of steady-state bifurcation diagrams as illustrated in Fig. 4 Non-Steady-State Behavior and Sensitivity of Protein Levels to miRs. The functional properties of the E2F/Myc/miR-17-92 network—in particular, the role of the miR cluster—can be further understood by studying its non-steady state kinetics. For example, the dynamics of the system can be very sensitive to the initial levels of the miR cluster. Shown in Fig. 5 and μ. In Fig. 5 0 but with 5 close values of μ0. All of the trajectories ultimately approach a stable steady state (shown as empty circle), but the initial conditions where μ0 = 0.340, 0.343, and 0.345 lead to trajectories with wide swings in protein levels that even surpass the upper steady state (see Fig. 4
At α′ = 0.1 (as in Fig. 5 in Fig. 5The non-steady state behavior of the system as shown in Fig. 5 to the maximum μ) correspond to increasing miR (μ) and decreasing protein ( ). This decrease in the protein, which is associated with increased miR, could then lead to a decreased rate of apoptosis—thus, the reference to the miR as antiapoptotic.miR-17-92 as an Oncogene and a Tumor Suppressor. Viewed in terms of miR steady state levels, the oncogenic and tumor suppressor properties of miR-17-92—cases a and d in Fig. 3 s that defines the cancer zone is chosen arbitrarily; one would expect that the range of the cancer zone would depend on the specific cellular system and on the perturbations of the system that drives it toward a cancerous state.) In the direction of the arrow in Fig. 6 s and μs increase—driving exit from the cancer zone and into apoptosis, thereby classifying the miR cluster as a tumor suppressor.
An alternative view of the oncogenic and tumor suppressor properties of miR-17-92—cases b and c in Fig. 3 The discussion in this section illustrates the confusion that may arise in using the labels “oncogene” and “tumor suppressor” if the attribute of the miR (that is, the miR level, μs, or the inhibition efficiency parameter, Γ′2) used to correlate with entry into or exit from the cancer zone is not clearly specified. However, determining Γ′2 experimentally would be more difficult in practice compared with measuring miR levels, and therefore classification using changes in miR levels is commonly used. Time Delays and Oscillations. In this section, Eqs. 6 and 4 are numerically solved. Fig. 7
Thus, the model with time delay predicts the coexistence between large-amplitude oscillations and low steady-state protein levels. To try to understand the physiological significance of these large-amplitude protein oscillations, we checked the stability of the lower branch of steady states (the off states) and found that these states are quite robust against perturbations—for example, at α′ = 0.1, it takes a perturbation of ≈370% above the value of s to switch the system to the large-amplitude oscillations (simulations not shown); also, large amounts of perturbation above μs do not induce switching, but, as shown in Fig. 5Conclusions We proposed and analyzed a simple model of the interactions between miR-17-92 and the transcription factors E2F and Myc. Our goal is to explore the broad consequences of the structure of the network on the levels, steady states and dynamics of the miR and the group of proteins that the miR targets. The simplicity of the 2-variable model precludes it from capturing the different properties of Myc, E2F1, E2F2, and E2F3 with respect to their proliferative or apoptotic effects or nature of repression by miR-17-92 members. The model couples the positive feedback loops involving E2F and Myc—generating bistability and the concomitant off-on switching behavior of the system—and the negative feedback loop between these proteins and members of the miR-17-92 cluster. The model predicts that the steady states of these proteins and the miRs change in the same direction, although slow non-steady state or transient dynamics are possible where the changes could be in opposite directions. We have illustrated how changes in the miR inhibition efficiency—the parameter Γ′2 in Eq. 3—controls the value of the off-on switch in growth-factor requirement and how it attenuates the on levels of the proteins. An important prediction of the model is that decreasing Γ′2 leads to decreasing growth-factor requirement for switching the protein on, and that the on levels increase with decreasing Γ′2. Possible experimental means of manipulating the value of Γ′2 are discussed. Due to the negative feedback loop in the network, large-amplitude protein oscillations are predicted to coexist with the off steady state levels, allowing the system to respond through apoptosis to dangerously large perturbations. Finally, using the postulate of a cancer zone, we have shown that the oncogenic and tumor suppressor properties of miR-17-92 parallel those of E2F and Myc. Methods Acknowledgments. This work was supported by U.S. National Science Foundation Agreement 0112050 and National Institutes of Health Grant RO-1HL67176. Footnotes The authors declare no conflict of interest. References 1. Gartel AL, Kandel ES. miRNAs: Little known mediators of oncogenesis. Semin Cancer Biol. 2008;18:103–110. [PubMed] 2. Mendell JT. myRiad roles for the miR-17-92 cluster in development and disease. Cell. 2008;133:217–222. [PubMed] 3. Watanabe Y, Tomita M, Kanai A. Computational methods for microRNA target prediction. Methods Enzymol. 2007;427:65–86. [PubMed] 4. Mazière P, Enright AJ. Prediction of microRNA targets. Drug Discov Today. 2007;12:452–458. [PubMed] 5. Gusev Y. Computational methods for analysis of cellular functions and pathways collectively targeted by differentially expressed microRNA. Methods. 2008;44:61–72. [PubMed] 6. Cho WC. OncomiRs: The discovery and progress of microRNAs in cancers. Mol Cancer. 2007;6:60. doi: 10.1186/1476–4598-6–60. [PubMed] 7. Aguda BD, Tang Y. The kinetic origins of the restriction point in the mammalian cell cycle. Cell Proliferation. 1999;32:321–335. [PubMed] 8. Aguda BD, Goryachev AB. From pathways databases to network models of switching behavior. PLoS Comput Biol. 2007;3:e152. 9. Aguda BD, Algar CK. Structural analysis of the qualitative networks regulating the cell cycle and apoptosis. Cell Cycle. 2003;2:538–544. [PubMed] 10. Tsang J, Zhu J, van Oudenaarden A. MicroRNA-mediated feedback and feedforward loops are recurrent network motifs in mammals. Mol Cell. 2007;26:753–767. [PubMed] 11. Li Y, Wang F, Lee JA, Gao FB. MicroRNA-9a ensures the precise specification of sensory organ precursors in Drosophila. Genes Dev. 2006;20:2793–2805. [PubMed] 12. Cohen SM, Brennecke J, Stark A. Denoising feedback loops by thresholding—a new role for microRNAs. Genes Dev. 2006;20:2769–2772. [PubMed] 13. Johnston RJ, Jr, Chang S, Etchberger JF, Ortiz CO, Hobert O. MicroRNAs acting in a double-negative feedback loop to control a neuronal cell fate decision. Proc Natl Acad Sci USA. 2005;102:12449–12454. [PubMed] 14. Coller HA, Forman JJ, Legesse-Miller A. Myc'ed Messages: Myc induces transcription of E2F1 while inhibiting its translation via a microRNA polycistron. PLoS Genet. 2007;3:e146. [PubMed] 15. He L, et al. A microRNA polycistron as a potential human oncogene. Nature. 2005;435:828–833. [PubMed] 16. Volinia S, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA. 2006;103:2257–2261. [PubMed] 17. Petrocca F, et al. E2F1-regulated microRNAs impair TGFβ-dependent cell cycle arrest and apoptosis in gastric cancer. Cancer Cell. 2008;13:272–286. [PubMed] 18. Johnson DG. The paradox of E2F1: Oncogene and tumor suppressor gene. Mol Carcinog. 2000;27:151–157. [PubMed] 19. Craciun G, Aguda BD, Friedman A. A detailed mathematical analysis of a modular network coordinating the cell cycle and apoptosis. Math Biosci Engineering. 2005;2:473–485. 20. Aguda BD, Clarke BL. Bistability in chemical reaction networks: Theory and application to the peroxidase–oxidase reaction. J Chem Phys. 1987;87:3461–3470. 21. Yao G, Lee TJ, Mori S, Nevins JR, You L. A bistable Rb-E2F switch underlies the restriction point. Nat Cell Biol. 2008;10:476–482. [PubMed] 22. Khanin R, Vinciotti V. Computational modeling of post-transcriptional gene regulation by microRNAs. J Comput Biol. 2008;15:305–316. [PubMed] 23. Hayashita Y, et al. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res. 2005;65:9628–9632. [PubMed] 24. Rinaldi A, et al. Concomitant MYC and microRNA cluster miR-17-92 (C13orf25) amplification in human mantle cell lymphoma. Leuk Lymphoma. 2007;48:410–412. [PubMed] 25. Sylvestre Y, et al. An E2F/miR-20a autoregulatory feedback loop. J Biol Chem. 2007;282:2135–2143. [PubMed] 26. Matsubara H, et al. Apoptosis induction by antisense oligonucleotides against miR-17–5p and miR-20a in lung cancers overexpressing miR-17-92. Oncogene. 2007;26:6099–6105. [PubMed] 27. Woods K, Thomson JM, Hammond SM. Direct regulation of an oncogenic microRNA cluster by E2F transcription factors. J Biol Chem. 2006;282:2130–2134. [PubMed] |
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||||||||||||||||||||||||
Semin Cancer Biol. 2008 Apr; 18(2):103-10.
[Semin Cancer Biol. 2008]Cell. 2008 Apr 18; 133(2):217-22.
[Cell. 2008]Methods Enzymol. 2007; 427():65-86.
[Methods Enzymol. 2007]Drug Discov Today. 2007 Jun; 12(11-12):452-8.
[Drug Discov Today. 2007]Methods. 2008 Jan; 44(1):61-72.
[Methods. 2008]Cell Prolif. 1999 Oct; 32(5):321-35.
[Cell Prolif. 1999]Cell Cycle. 2003 Nov-Dec; 2(6):538-44.
[Cell Cycle. 2003]Mol Cell. 2007 Jun 8; 26(5):753-67.
[Mol Cell. 2007]Genes Dev. 2006 Oct 15; 20(20):2793-805.
[Genes Dev. 2006]Genes Dev. 2006 Oct 15; 20(20):2769-72.
[Genes Dev. 2006]Proc Natl Acad Sci U S A. 2005 Aug 30; 102(35):12449-54.
[Proc Natl Acad Sci U S A. 2005]Mol Cancer. 2007 Sep 25; 6():60.
[Mol Cancer. 2007]Cell. 2008 Apr 18; 133(2):217-22.
[Cell. 2008]Nature. 2005 Jun 9; 435(7043):828-33.
[Nature. 2005]Proc Natl Acad Sci U S A. 2006 Feb 14; 103(7):2257-61.
[Proc Natl Acad Sci U S A. 2006]Cancer Cell. 2008 Mar; 13(3):272-86.
[Cancer Cell. 2008]PLoS Genet. 2007 Aug; 3(8):e146.
[PLoS Genet. 2007]PLoS Genet. 2007 Aug; 3(8):e146.
[PLoS Genet. 2007]PLoS Genet. 2007 Aug; 3(8):e146.
[PLoS Genet. 2007]Mol Carcinog. 2000 Mar; 27(3):151-7.
[Mol Carcinog. 2000]Cell Cycle. 2003 Nov-Dec; 2(6):538-44.
[Cell Cycle. 2003]Nat Cell Biol. 2008 Apr; 10(4):476-82.
[Nat Cell Biol. 2008]J Comput Biol. 2008 Apr; 15(3):305-16.
[J Comput Biol. 2008]Cancer Res. 2005 Nov 1; 65(21):9628-32.
[Cancer Res. 2005]Leuk Lymphoma. 2007 Feb; 48(2):410-2.
[Leuk Lymphoma. 2007]Nat Cell Biol. 2008 Apr; 10(4):476-82.
[Nat Cell Biol. 2008]PLoS Genet. 2007 Aug; 3(8):e146.
[PLoS Genet. 2007]J Biol Chem. 2007 Jan 26; 282(4):2135-43.
[J Biol Chem. 2007]Oncogene. 2007 Sep 6; 26(41):6099-105.
[Oncogene. 2007]J Biol Chem. 2007 Jan 26; 282(4):2130-4.
[J Biol Chem. 2007]